uniQure N.V.

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, VRTX has a market cap of 108.8B. Regarding current trading prices, QURE is priced at $22.82, while VRTX trades at $427.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas VRTX's P/E ratio is 25.37. In terms of profitability, QURE's ROE is -1.46%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, QURE is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check VRTX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, REGN has a market cap of 74.3B. Regarding current trading prices, QURE is priced at $22.82, while REGN trades at $721.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas REGN's P/E ratio is 17.59. In terms of profitability, QURE's ROE is -1.46%, compared to REGN's ROE of +0.14%. Regarding short-term risk, QURE is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check REGN's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, QURE is priced at $22.82, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas VRNA's P/E ratio is -102.80. In terms of profitability, QURE's ROE is -1.46%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, QURE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check VRNA's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ARGX has a market cap of 50B. Regarding current trading prices, QURE is priced at $22.82, while ARGX trades at $807.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ARGX's P/E ratio is 41.31. In terms of profitability, QURE's ROE is -1.46%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, QURE is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ARGX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, QURE is priced at $22.82, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas SGEN's P/E ratio is -57.19. In terms of profitability, QURE's ROE is -1.46%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, QURE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check SGEN's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ALNY has a market cap of 40.4B. Regarding current trading prices, QURE is priced at $22.82, while ALNY trades at $303.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ALNY's P/E ratio is 76.32. In terms of profitability, QURE's ROE is -1.46%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, QURE is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ALNY's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, RVMD has a market cap of 32.1B. Regarding current trading prices, QURE is priced at $22.82, while RVMD trades at $151.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas RVMD's P/E ratio is -25.36. In terms of profitability, QURE's ROE is -1.46%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, QURE is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check RVMD's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, INSM has a market cap of 29.6B. Regarding current trading prices, QURE is priced at $22.82, while INSM trades at $137.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas INSM's P/E ratio is -21.38. In terms of profitability, QURE's ROE is -1.46%, compared to INSM's ROE of -1.68%. Regarding short-term risk, QURE is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check INSM's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, UTHR has a market cap of 26.1B. Regarding current trading prices, QURE is priced at $22.82, while UTHR trades at $596.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas UTHR's P/E ratio is 21.40. In terms of profitability, QURE's ROE is -1.46%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, QURE is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check UTHR's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, BNTX has a market cap of 23.9B. Regarding current trading prices, QURE is priced at $22.82, while BNTX trades at $95.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas BNTX's P/E ratio is -16.01. In terms of profitability, QURE's ROE is -1.46%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, QURE is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check BNTX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, RPRX has a market cap of 21.7B. Regarding current trading prices, QURE is priced at $22.82, while RPRX trades at $50.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas RPRX's P/E ratio is 28.48. In terms of profitability, QURE's ROE is -1.46%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, QURE is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check RPRX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ROIV has a market cap of 20.6B. Regarding current trading prices, QURE is priced at $22.82, while ROIV trades at $28.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ROIV's P/E ratio is -24.62. In terms of profitability, QURE's ROE is -1.46%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, QURE is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ROIV's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, QURE is priced at $22.82, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas BGNE's P/E ratio is -22.55. In terms of profitability, QURE's ROE is -1.46%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, QURE is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check BGNE's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, INCY has a market cap of 19.9B. Regarding current trading prices, QURE is priced at $22.82, while INCY trades at $99.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas INCY's P/E ratio is 14.06. In terms of profitability, QURE's ROE is -1.46%, compared to INCY's ROE of +0.29%. Regarding short-term risk, QURE is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check INCY's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, MRNA has a market cap of 19.3B. Regarding current trading prices, QURE is priced at $22.82, while MRNA trades at $48.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas MRNA's P/E ratio is -6.72. In terms of profitability, QURE's ROE is -1.46%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, QURE is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check MRNA's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, QURE is priced at $22.82, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, QURE's ROE is -1.46%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, QURE is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check DNA-WT's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, GMAB has a market cap of 17.2B. Regarding current trading prices, QURE is priced at $22.82, while GMAB trades at $27.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas GMAB's P/E ratio is 18.12. In terms of profitability, QURE's ROE is -1.46%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, QURE is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check GMAB's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ASND has a market cap of 14.5B. Regarding current trading prices, QURE is priced at $22.82, while ASND trades at $235.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ASND's P/E ratio is -53.36. In terms of profitability, QURE's ROE is -1.46%, compared to ASND's ROE of +1.28%. Regarding short-term risk, QURE is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ASND's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, JAZZ has a market cap of 14.3B. Regarding current trading prices, QURE is priced at $22.82, while JAZZ trades at $228.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas JAZZ's P/E ratio is 2075.36. In terms of profitability, QURE's ROE is -1.46%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, QURE is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check JAZZ's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, SMMT has a market cap of 13.8B. Regarding current trading prices, QURE is priced at $22.82, while SMMT trades at $17.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas SMMT's P/E ratio is -11.23. In terms of profitability, QURE's ROE is -1.46%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, QURE is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check SMMT's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, QURE is priced at $22.82, while BBIO trades at $68.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas BBIO's P/E ratio is -18.01. In terms of profitability, QURE's ROE is -1.46%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, QURE is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check BBIO's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, IONS has a market cap of 12.7B. Regarding current trading prices, QURE is priced at $22.82, while IONS trades at $76.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas IONS's P/E ratio is -38.23. In terms of profitability, QURE's ROE is -1.46%, compared to IONS's ROE of -0.59%. Regarding short-term risk, QURE is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check IONS's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, QURE is priced at $22.82, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas KRTX's P/E ratio is -28.09. In terms of profitability, QURE's ROE is -1.46%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, QURE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check KRTX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, EXEL has a market cap of 12.4B. Regarding current trading prices, QURE is priced at $22.82, while EXEL trades at $48.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas EXEL's P/E ratio is 16.12. In terms of profitability, QURE's ROE is -1.46%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, QURE is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check EXEL's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, MDGL has a market cap of 12.4B. Regarding current trading prices, QURE is priced at $22.82, while MDGL trades at $539.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas MDGL's P/E ratio is -41.91. In terms of profitability, QURE's ROE is -1.46%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, QURE is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check MDGL's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, AXSM has a market cap of 11.5B. Regarding current trading prices, QURE is priced at $22.82, while AXSM trades at $222.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas AXSM's P/E ratio is -59.68. In terms of profitability, QURE's ROE is -1.46%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, QURE is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check AXSM's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, QURE is priced at $22.82, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas RNAM's P/E ratio is -17.39. In terms of profitability, QURE's ROE is -1.46%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, QURE is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check RNAM's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ARWR has a market cap of 11.1B. Regarding current trading prices, QURE is priced at $22.82, while ARWR trades at $79.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ARWR's P/E ratio is 49.47. In terms of profitability, QURE's ROE is -1.46%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, QURE is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ARWR's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, BMRN has a market cap of 10.5B. Regarding current trading prices, QURE is priced at $22.82, while BMRN trades at $54.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas BMRN's P/E ratio is 39.29. In terms of profitability, QURE's ROE is -1.46%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, QURE is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check BMRN's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, QURE is priced at $22.82, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas RXDX's P/E ratio is -56.47. In terms of profitability, QURE's ROE is -1.46%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, QURE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check RXDX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, QURE is priced at $22.82, while CYTK trades at $74.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CYTK's P/E ratio is -11.44. In terms of profitability, QURE's ROE is -1.46%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, QURE is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CYTK's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, QURE is priced at $22.82, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas IMGN's P/E ratio is -111.55. In terms of profitability, QURE's ROE is -1.46%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, QURE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check IMGN's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, IBRX has a market cap of 8.6B. Regarding current trading prices, QURE is priced at $22.82, while IBRX trades at $8.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas IBRX's P/E ratio is -20.97. In terms of profitability, QURE's ROE is -1.46%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, QURE is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check IBRX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, KRYS has a market cap of 8.5B. Regarding current trading prices, QURE is priced at $22.82, while KRYS trades at $288.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas KRYS's P/E ratio is 38.63. In terms of profitability, QURE's ROE is -1.46%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, QURE is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check KRYS's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, QURE is priced at $22.82, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas BPMC's P/E ratio is -51.58. In terms of profitability, QURE's ROE is -1.46%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, QURE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check BPMC's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ABVX has a market cap of 8.3B. Regarding current trading prices, QURE is priced at $22.82, while ABVX trades at $126.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ABVX's P/E ratio is -22.33. In terms of profitability, QURE's ROE is -1.46%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, QURE is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ABVX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, QURE is priced at $22.82, while PCVX trades at $57.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas PCVX's P/E ratio is -10.14. In terms of profitability, QURE's ROE is -1.46%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, QURE is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check PCVX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, QURE is priced at $22.82, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CERE's P/E ratio is -16.47. In terms of profitability, QURE's ROE is -1.46%, compared to CERE's ROE of -0.72%. Regarding short-term risk, QURE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CERE's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, HALO has a market cap of 7.9B. Regarding current trading prices, QURE is priced at $22.82, while HALO trades at $66.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas HALO's P/E ratio is 25.93. In terms of profitability, QURE's ROE is -1.46%, compared to HALO's ROE of +0.93%. Regarding short-term risk, QURE is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check HALO's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, QURE is priced at $22.82, while NUVL trades at $104.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas NUVL's P/E ratio is -17.83. In terms of profitability, QURE's ROE is -1.46%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, QURE is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check NUVL's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, QURE is priced at $22.82, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas MTSR's P/E ratio is -23.58. In terms of profitability, QURE's ROE is -1.46%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, QURE is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check MTSR's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, TECH has a market cap of 7.4B. Regarding current trading prices, QURE is priced at $22.82, while TECH trades at $47.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas TECH's P/E ratio is 89.44. In terms of profitability, QURE's ROE is -1.46%, compared to TECH's ROE of +0.05%. Regarding short-term risk, QURE is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for QURE.Check TECH's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, QURE is priced at $22.82, while PRAX trades at $338.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas PRAX's P/E ratio is -25.09. In terms of profitability, QURE's ROE is -1.46%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, QURE is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check PRAX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, KYMR has a market cap of 7B. Regarding current trading prices, QURE is priced at $22.82, while KYMR trades at $86.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas KYMR's P/E ratio is -24.09. In terms of profitability, QURE's ROE is -1.46%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, QURE is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check KYMR's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, QURE is priced at $22.82, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas MRUS's P/E ratio is -17.05. In terms of profitability, QURE's ROE is -1.46%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, QURE is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check MRUS's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CELC has a market cap of 6.7B. Regarding current trading prices, QURE is priced at $22.82, while CELC trades at $139.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CELC's P/E ratio is -31.81. In terms of profitability, QURE's ROE is -1.46%, compared to CELC's ROE of -2.03%. Regarding short-term risk, QURE is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CELC's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, QURE is priced at $22.82, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ACLX's P/E ratio is -28.27. In terms of profitability, QURE's ROE is -1.46%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, QURE is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ACLX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, TGTX has a market cap of 6.7B. Regarding current trading prices, QURE is priced at $22.82, while TGTX trades at $41.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas TGTX's P/E ratio is 15.15. In terms of profitability, QURE's ROE is -1.46%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, QURE is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for QURE.Check TGTX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, PTGX has a market cap of 6.6B. Regarding current trading prices, QURE is priced at $22.82, while PTGX trades at $103.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas PTGX's P/E ratio is -50.73. In terms of profitability, QURE's ROE is -1.46%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, QURE is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check PTGX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, RYTM has a market cap of 6.6B. Regarding current trading prices, QURE is priced at $22.82, while RYTM trades at $96.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas RYTM's P/E ratio is -30.87. In terms of profitability, QURE's ROE is -1.46%, compared to RYTM's ROE of -2.04%. Regarding short-term risk, QURE is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check RYTM's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, QURE is priced at $22.82, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas RETA's P/E ratio is -66.29. In terms of profitability, QURE's ROE is -1.46%, compared to RETA's ROE of +0.47%. Regarding short-term risk, QURE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check RETA's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, QURE is priced at $22.82, while BLTE trades at $156.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas BLTE's P/E ratio is -67.68. In terms of profitability, QURE's ROE is -1.46%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, QURE is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check BLTE's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, QURE is priced at $22.82, while CNTA trades at $39.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CNTA's P/E ratio is -27.13. In terms of profitability, QURE's ROE is -1.46%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, QURE is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CNTA's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ALKS has a market cap of 5.9B. Regarding current trading prices, QURE is priced at $22.82, while ALKS trades at $35.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ALKS's P/E ratio is 39.23. In terms of profitability, QURE's ROE is -1.46%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, QURE is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ALKS's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, IMVT has a market cap of 5.8B. Regarding current trading prices, QURE is priced at $22.82, while IMVT trades at $28.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas IMVT's P/E ratio is -10.74. In terms of profitability, QURE's ROE is -1.46%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, QURE is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check IMVT's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, COGT has a market cap of 5.8B. Regarding current trading prices, QURE is priced at $22.82, while COGT trades at $35.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas COGT's P/E ratio is -16.54. In terms of profitability, QURE's ROE is -1.46%, compared to COGT's ROE of -0.83%. Regarding short-term risk, QURE is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check COGT's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, QURE is priced at $22.82, while CGON trades at $68.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CGON's P/E ratio is -32.69. In terms of profitability, QURE's ROE is -1.46%, compared to CGON's ROE of -0.23%. Regarding short-term risk, QURE is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CGON's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, QURE is priced at $22.82, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CDTX's P/E ratio is -19.77. In terms of profitability, QURE's ROE is -1.46%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, QURE is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CDTX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CORT has a market cap of 5.6B. Regarding current trading prices, QURE is priced at $22.82, while CORT trades at $52.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CORT's P/E ratio is 148.91. In terms of profitability, QURE's ROE is -1.46%, compared to CORT's ROE of +0.08%. Regarding short-term risk, QURE is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CORT's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, QURE is priced at $22.82, while PTCT trades at $66.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas PTCT's P/E ratio is 7.76. In terms of profitability, QURE's ROE is -1.46%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, QURE is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check PTCT's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, QURE is priced at $22.82, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, QURE's ROE is -1.46%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, QURE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ABCM's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, MIRM has a market cap of 5.5B. Regarding current trading prices, QURE is priced at $22.82, while MIRM trades at $110.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas MIRM's P/E ratio is -233.83. In terms of profitability, QURE's ROE is -1.46%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, QURE is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check MIRM's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, QURE is priced at $22.82, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ISEE's P/E ratio is -22.44. In terms of profitability, QURE's ROE is -1.46%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, QURE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ISEE's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CAI has a market cap of 5.4B. Regarding current trading prices, QURE is priced at $22.82, while CAI trades at $19.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CAI's P/E ratio is -5.94. In terms of profitability, QURE's ROE is -1.46%, compared to CAI's ROE of +0.25%. Regarding short-term risk, QURE is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CAI's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, SRRK has a market cap of 5.4B. Regarding current trading prices, QURE is priced at $22.82, while SRRK trades at $47.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas SRRK's P/E ratio is -14.31. In terms of profitability, QURE's ROE is -1.46%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, QURE is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check SRRK's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, LEGN has a market cap of 5.4B. Regarding current trading prices, QURE is priced at $22.82, while LEGN trades at $28.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas LEGN's P/E ratio is -17.86. In terms of profitability, QURE's ROE is -1.46%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, QURE is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check LEGN's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, QURE is priced at $22.82, while CRSP trades at $55.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CRSP's P/E ratio is -8.93. In terms of profitability, QURE's ROE is -1.46%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, QURE is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CRSP's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, QURE is priced at $22.82, while APLS trades at $41.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas APLS's P/E ratio is 228.14. In terms of profitability, QURE's ROE is -1.46%, compared to APLS's ROE of +0.08%. Regarding short-term risk, QURE is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check APLS's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, APGE has a market cap of 5.2B. Regarding current trading prices, QURE is priced at $22.82, while APGE trades at $84.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas APGE's P/E ratio is -20.06. In terms of profitability, QURE's ROE is -1.46%, compared to APGE's ROE of -0.37%. Regarding short-term risk, QURE is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check APGE's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, QURE is priced at $22.82, while FBIOX trades at $25.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas FBIOX's P/E ratio is N/A. In terms of profitability, QURE's ROE is -1.46%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, QURE is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check FBIOX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, QURE is priced at $22.82, while TERN trades at $52.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas TERN's P/E ratio is -51.42. In terms of profitability, QURE's ROE is -1.46%, compared to TERN's ROE of -0.20%. Regarding short-term risk, QURE is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check TERN's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, QURE is priced at $22.82, while LGND trades at $232.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas LGND's P/E ratio is 37.87. In terms of profitability, QURE's ROE is -1.46%, compared to LGND's ROE of +0.14%. Regarding short-term risk, QURE is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check LGND's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, QURE is priced at $22.82, while XENE trades at $58.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas XENE's P/E ratio is -13.43. In terms of profitability, QURE's ROE is -1.46%, compared to XENE's ROE of -0.56%. Regarding short-term risk, QURE is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check XENE's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, QURE is priced at $22.82, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas FOLD's P/E ratio is -161.00. In terms of profitability, QURE's ROE is -1.46%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, QURE is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check FOLD's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, QURE is priced at $22.82, while MANE trades at $109.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas MANE's P/E ratio is -46.03. In terms of profitability, QURE's ROE is -1.46%, compared to MANE's ROE of -0.76%. Regarding short-term risk, QURE is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check MANE's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, QURE is priced at $22.82, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas AKRO's P/E ratio is -14.57. In terms of profitability, QURE's ROE is -1.46%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, QURE is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check AKRO's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, QURE is priced at $22.82, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ALPN's P/E ratio is -101.52. In terms of profitability, QURE's ROE is -1.46%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, QURE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ALPN's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, QURE is priced at $22.82, while SYRE trades at $73.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas SYRE's P/E ratio is -36.87. In terms of profitability, QURE's ROE is -1.46%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, QURE is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check SYRE's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CRNX has a market cap of 4.4B. Regarding current trading prices, QURE is priced at $22.82, while CRNX trades at $41.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CRNX's P/E ratio is -8.43. In terms of profitability, QURE's ROE is -1.46%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, QURE is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CRNX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, KNSA has a market cap of 4.3B. Regarding current trading prices, QURE is priced at $22.82, while KNSA trades at $58.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas KNSA's P/E ratio is 61.26. In terms of profitability, QURE's ROE is -1.46%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, QURE is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check KNSA's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, QURE is priced at $22.82, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas OPT's P/E ratio is -1.52. In terms of profitability, QURE's ROE is -1.46%, compared to OPT's ROE of +0.88%. Regarding short-term risk, QURE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check OPT's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, TVTX has a market cap of 4.2B. Regarding current trading prices, QURE is priced at $22.82, while TVTX trades at $44.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas TVTX's P/E ratio is -89.53. In terms of profitability, QURE's ROE is -1.46%, compared to TVTX's ROE of -0.58%. Regarding short-term risk, QURE is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check TVTX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, QURE is priced at $22.82, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas MRTX's P/E ratio is -4.82. In terms of profitability, QURE's ROE is -1.46%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, QURE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check MRTX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, EWTX has a market cap of 4B. Regarding current trading prices, QURE is priced at $22.82, while EWTX trades at $36.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas EWTX's P/E ratio is -22.69. In terms of profitability, QURE's ROE is -1.46%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, QURE is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check EWTX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, QURE is priced at $22.82, while TLX trades at $11.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas TLX's P/E ratio is -555.75. In terms of profitability, QURE's ROE is -1.46%, compared to TLX's ROE of -0.02%. Regarding short-term risk, QURE is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check TLX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, QURE is priced at $22.82, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas RYZB's P/E ratio is -57.86. In terms of profitability, QURE's ROE is -1.46%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, QURE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check RYZB's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, QURE is priced at $22.82, while VKTX trades at $32.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas VKTX's P/E ratio is -7.78. In terms of profitability, QURE's ROE is -1.46%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, QURE is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check VKTX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CPRX has a market cap of 3.7B. Regarding current trading prices, QURE is priced at $22.82, while CPRX trades at $30.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CPRX's P/E ratio is 18.17. In terms of profitability, QURE's ROE is -1.46%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, QURE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CPRX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, QURE is priced at $22.82, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas CBAY's P/E ratio is -32.81. In terms of profitability, QURE's ROE is -1.46%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, QURE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check CBAY's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, LQDA has a market cap of 3.7B. Regarding current trading prices, QURE is priced at $22.82, while LQDA trades at $42.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas LQDA's P/E ratio is -52.67. In terms of profitability, QURE's ROE is -1.46%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, QURE is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check LQDA's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, QURE is priced at $22.82, while ACAD trades at $21.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ACAD's P/E ratio is 9.34. In terms of profitability, QURE's ROE is -1.46%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, QURE is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ACAD's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, QURE is priced at $22.82, while NAMS trades at $30.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas NAMS's P/E ratio is -18.03. In terms of profitability, QURE's ROE is -1.46%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, QURE is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check NAMS's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, QURE is priced at $22.82, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas SWTX's P/E ratio is -13.78. In terms of profitability, QURE's ROE is -1.46%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, QURE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check SWTX's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, DNTH has a market cap of 3.5B. Regarding current trading prices, QURE is priced at $22.82, while DNTH trades at $90.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas DNTH's P/E ratio is -21.52. In terms of profitability, QURE's ROE is -1.46%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, QURE is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check DNTH's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, ERAS has a market cap of 3.4B. Regarding current trading prices, QURE is priced at $22.82, while ERAS trades at $10.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas ERAS's P/E ratio is -24.77. In terms of profitability, QURE's ROE is -1.46%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, QURE is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check ERAS's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, BEAM has a market cap of 3.3B. Regarding current trading prices, QURE is priced at $22.82, while BEAM trades at $32.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas BEAM's P/E ratio is -39.93. In terms of profitability, QURE's ROE is -1.46%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, QURE is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check BEAM's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, VCYT has a market cap of 3.3B. Regarding current trading prices, QURE is priced at $22.82, while VCYT trades at $41.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas VCYT's P/E ratio is 38.20. In terms of profitability, QURE's ROE is -1.46%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, QURE is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for QURE.Check VCYT's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, QURE is priced at $22.82, while DNLI trades at $20.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas DNLI's P/E ratio is -6.86. In terms of profitability, QURE's ROE is -1.46%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, QURE is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check DNLI's competition here

QURE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QURE stands at 1.4B. In comparison, KLRA has a market cap of 3.2B. Regarding current trading prices, QURE is priced at $22.82, while KLRA trades at $24.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QURE currently has a P/E ratio of -6.54, whereas KLRA's P/E ratio is -19.58. In terms of profitability, QURE's ROE is -1.46%, compared to KLRA's ROE of N/A. Regarding short-term risk, QURE is more volatile compared to KLRA. This indicates potentially higher risk in terms of short-term price fluctuations for QURE.Check KLRA's competition here